CTF was thrilled to recently announce that our long-time partner, SpringWorks Therapeutics, has received FDA Priority Review for mirdametinib, a potential new treatment for NF1-associated plexiform neurofibromas. This marks a significant milestone for patients, particularly adults who currently lack approved therapies. CTF played a key role in the formation of SpringWorks and in driving the drug repositioning strategy that led to this promising development. |